Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.55 |
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | DRD3 | P35462 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7426690 | 0.85 | DRD4 (0.68) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL13568797 | 0.82 | ALDH1A1 (0.71) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL418557 | 0.79 | DRD4 (0.57) | DRD4DRD2DRD3ALDH1A1TDP1 | |
| SCHEMBL1537856 | 0.78 | KDM4E (0.55) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL18699541 | 0.78 | DRD2 (0.48) | DRD4DRD2DRD3ALDH1A1TDP1 | |
| SCHEMBL28327332 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KDM4EPOLBTSHRMAPT | |
| Ammonia Solution, Strong SCHEMBL27497850 | 0.77 | KDM4E (0.54) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL18699453 | 0.77 | DRD4 (0.47) | DRD4DRD2DRD3ALDH1A1TDP1 | |
| SCHEMBL1740639 | 0.77 | ALDH1A1 (0.46) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL15937598 | 0.74 | DRD4 (0.67) | DRD4DRD2DRD3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557098-B2 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557098-B2 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| US-7541370-B2 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541370-B2 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080200455-A1 | 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands | WYETH (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200455-A1 | 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands | WYETH (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080064684-A1 | Sub-type selective serotonin receptor agonists; antidepressants; schizophrenia, Alzheimer's Disease, Parkinson's Disease; alkylation or amidation of the heterocyclylbenzazole with an alkylhalide or acylhalide | WYETH (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064684-A1 | Sub-type selective serotonin receptor agonists; antidepressants; schizophrenia, Alzheimer's Disease, Parkinson's Disease; alkylation or amidation of the heterocyclylbenzazole with an alkylhalide or acylhalide | WYETH (US) | 2008-03-13 | — | — | US | disclosed |
| US-7282495-B2 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282495-B2 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-16 | — | — | US | disclosed |
| EP-0660832-B1 | SEROTONIN RECEPTOR AGENTS | MERRELL PHARMA INC (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5436246-A | Compounds for treatment of anxiety, depression, migraine, stroke, angina and hypertension | MERRELL DOW PHARMACEUTICALS INC. | 1995-07-25 | — | — | US | disclosed |
| EP-0660832-A1 | SEROTONIN RECEPTOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994006789-A1 | SEROTONIN RECEPTOR AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064684-A1 | Sub-type selective serotonin receptor agonists; antidepressants; schizophrenia, Alzheimer's Disease, Parkinson's Disease; alkylation or amidation of the heterocyclylbenzazole with an alkylhalide or acylhalide | HTR6, HTR3B, HTR2B | DRD4 47/4885DRD2 29/4885DRD3 88/4885 |
| US-20080200455-A1 | 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands | HTR6, HTR1B, HTR1A | DRD4 463/4885DRD2 250/4885DRD3 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.